🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China businesswire.com/news/home/2024…

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy businesswire.com/news/home/2024…

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA businesswire.com/news/home/2024…

Summit Raises $200 Million at Premium to Previous Closing Price In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa businesswire.com/news/home/2024…

Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors businesswire.com/news/home/2024…

Summit Therapeutics and MD Anderson (MD Anderson Cancer Center) Announce Strategic Collaboration to Accelerate Development of Ivonescimab Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials businesswire.com/news/home/2024…

We are excited to begin our collaboration with MD Anderson Cancer Center to accelerate the development of ivonescimab

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at #WCLC24 Additionally, Ivonescimab Phase II Data in Perioperative Setting for Resectable NSCLC to be Presented at IASLC's World Lung businesswire.com/news/home/2024…

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China businesswire.com/news/home/2024…

Summit Therapeutics $SMMT shares nearly doubling this week after its lung cancer drug beat Merck's Keytruda in a head-to-head trial. Summit Therapeutics CEOs Bob Duggan and Maky Zanganeh explain what's ahead for the treatment, and the potential impact of the BIOSECURE Act.

Summit Therapeutics Raises $235 Million Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at Sept 11 2024 Closing Price of $22.70 businesswire.com/news/home/2024…

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 businesswire.com/news/home/2024…

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC Topline data from the HARMONi Trial Is Expected in Mid-2025 businesswire.com/news/home/2024…

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference businesswire.com/news/home/2025…

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China businesswire.com/news/home/2025…

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 businesswire.com/news/home/2025…

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China businesswire.com/news/home/2025…

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 businesswire.com/news/home/2025…

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study businesswire.com/news/home/2025…

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference businesswire.com/news/home/2025…